Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:How the experts currently use CDK4/6 inhibitors in clinical practiceClinical implications of key studies on CDK4/6 inhibitors from ASCO 2021Strategies for counseling patients receiving CDK4/6 inhibitorsPresenters:Joyce O’Shaughnessy, MDCelebrating Women Chair in Breast Cancer ResearchDirector, Breast Cancer Research ProgramBaylor University Medical CenterTexas OncologyUS Oncology NetworkDallas, TexasMatthew P. Goetz, MDErivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.Professor of Oncology and PharmacologyDirector, Mayo Clinic Breast Cancer SPORECo-Leader, Women's Cancer Program, Mayo Clinic Cancer CenterCo-Chair, Mayo Breast Disease GroupDepartment of Medical OncologyMayo ClinicRochester, MinnesotaSara Hurvitz, MD, FACPProfessor of MedicineDirector, Breast Oncology ProgramDivision of Hematology-OncologyDepartment of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaLink to the full program:bit.ly/3kaJKeC

There are no comments yet.

Please log in to write the first comment.